Literature DB >> 23962611

Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design.

D V L Rhodes1, C G Earnhart, T N Mather, P F M Meeus, R T Marconi.   

Abstract

In endemic regions, Lyme disease is a potential health threat to dogs. Canine Lyme disease manifests with arthritis-induced lameness, anorexia, fever, lethargy, lymphadenopathy and, in some cases, fatal glomerulonephritis. A recent study revealed that the regional mean for the percentage of seropositive dogs in the north-east of the USA is 11.6%. The outer surface protein C (OspC) of Lyme disease spirochetes is an important virulence factor required for the establishment of infection in mammals. It is a leading candidate in human and canine Lyme disease vaccine development efforts. Over 30 distinct ospC phyletic types have been defined. It has been hypothesized that ospC genotype may influence mammalian host range. In this study, Ixodes scapularis ticks collected from the field in Rhode Island were assessed for infection with B. burgdorferi. Ticks were fed on purpose bred beagles to repletion and infection of the dogs was assessed through serology and PCR. Tissue biopsies (n=2) were collected from each dog 49 days post-tick infestation (dpi) and the ospC genotype of the infecting strains determined by direct PCR of DNA extracted from tissue or by PCR after cultivation of spirochetes from biopsy samples. The dominant ospC types associated with B. burgdorferi canine infections differed from those associated with human infection, indicating a relationship between ospC sequence and preferred host range. Knowledge of the most common ospC genotypes associated specifically with infection of dogs will facilitate the rational design of OspC-based canine Lyme disease vaccines and diagnostic assays.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Borrelia burgdorferi; Canine; Lyme disease; OspC; Ticks; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 23962611      PMCID: PMC3872846          DOI: 10.1016/j.tvjl.2013.07.019

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  41 in total

1.  Evidence for the contribution of point mutations to vlsE variation and for apparent constraints on the net accumulation of sequence changes in vlsE during infection with Lyme disease spirochetes.

Authors:  S Y Sung; J V McDowell; R T Marconi
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

2.  Identification of a third genomic group of Borrelia burgdorferi through signature nucleotide analysis and 16S rRNA sequence determination.

Authors:  R T Marconi; C F Garon
Journal:  J Gen Microbiol       Date:  1992-03

3.  Geographic uniformity of the Lyme disease spirochete (Borrelia burgdorferi) and its shared history with tick vector (Ixodes scapularis) in the Northeastern United States.

Authors:  Wei-Gang Qiu; Daniel E Dykhuizen; Michael S Acosta; Benjamin J Luft
Journal:  Genetics       Date:  2002-03       Impact factor: 4.562

4.  OspC is potent plasminogen receptor on surface of Borrelia burgdorferi.

Authors:  Özlem Önder; Parris T Humphrey; Brian McOmber; Farida Korobova; Nicholas Francella; Doron C Greenbaum; Dustin Brisson
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

5.  Spirochetes isolated from the blood of two patients with Lyme disease.

Authors:  J L Benach; E M Bosler; J P Hanrahan; J L Coleman; G S Habicht; T F Bast; D J Cameron; J L Ziegler; A G Barbour; W Burgdorfer; R Edelman; R A Kaslow
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

6.  Lyme disease-a tick-borne spirochetosis?

Authors:  W Burgdorfer; A G Barbour; S F Hayes; J L Benach; E Grunwaldt; J P Davis
Journal:  Science       Date:  1982-06-18       Impact factor: 47.728

7.  Molecular analysis and expression of a Borrelia burgdorferi gene encoding a 22 kDa protein (pC) in Escherichia coli.

Authors:  R Fuchs; S Jauris; F Lottspeich; V Preac-Mursic; B Wilske; E Soutschek
Journal:  Mol Microbiol       Date:  1992-02       Impact factor: 3.501

8.  Infection with multiple strains of Borrelia burgdorferi sensu stricto in patients with Lyme disease.

Authors:  G Seinost; W T Golde; B W Berger; J J Dunn; D Qiu; D S Dunkin; D E Dykhuizen; B J Luft; R J Dattwyler
Journal:  Arch Dermatol       Date:  1999-11

9.  ospC diversity in Borrelia burgdorferi: different hosts are different niches.

Authors:  Dustin Brisson; Daniel E Dykhuizen
Journal:  Genetics       Date:  2004-10       Impact factor: 4.562

10.  Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.

Authors:  G Baranton; D Postic; I Saint Girons; P Boerlin; J C Piffaretti; M Assous; P A Grimont
Journal:  Int J Syst Bacteriol       Date:  1992-07
View more
  14 in total

Review 1.  Diversity of the Lyme Disease Spirochetes and its Influence on Immune Responses to Infection and Vaccination.

Authors:  Jerilyn R Izac; Richard T Marconi
Journal:  Vet Clin North Am Small Anim Pract       Date:  2019-04-06       Impact factor: 2.093

2.  Analysis of the antigenic determinants of the OspC protein of the Lyme disease spirochetes: Evidence that the C10 motif is not immunodominant or required to elicit bactericidal antibody responses.

Authors:  Jerilyn R Izac; Andrew C Camire; Christopher G Earnhart; Monica E Embers; Rebecca A Funk; Edward B Breitschwerdt; Richard T Marconi
Journal:  Vaccine       Date:  2019-03-25       Impact factor: 3.641

3.  Delineating Surface Epitopes of Lyme Disease Pathogen Targeted by Highly Protective Antibodies of New Zealand White Rabbits.

Authors:  Artem S Rogovskyy; Salvador Eugenio C Caoili; Yurij Ionov; Helen Piontkivska; Pavel Skums; Viachaslau Tsyvina; Alex Zelikovsky; Suryakant D Waghela
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

4.  Antibody profiling of a Borreliella burgdorferi (Lyme disease) C6 antibody positive, symptomatic Rottweiler and her pups.

Authors:  A L Hatke; D R Green; K Stasiak; R T Marconi
Journal:  Vet J       Date:  2020-07-05       Impact factor: 2.688

5.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

6.  Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.

Authors:  Jerilyn R Izac; Lee D Oliver; Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2017-05-04       Impact factor: 3.641

7.  Comparison of effectiveness of cefovecin, doxycycline, and amoxicillin for the treatment of experimentally induced early Lyme borreliosis in dogs.

Authors:  Bettina Wagner; John Johnson; David Garcia-Tapia; Nicole Honsberger; Vickie King; Catherine Strietzel; John M Hardham; Thomas J Heinz; Richard T Marconi; Patrick F M Meeus
Journal:  BMC Vet Res       Date:  2015-07-25       Impact factor: 2.741

8.  A Bayesian spatio-temporal model for forecasting the prevalence of antibodies to Borrelia burgdorferi, causative agent of Lyme disease, in domestic dogs within the contiguous United States.

Authors:  Stella C Watson; Yan Liu; Robert B Lund; Jenna R Gettings; Shila K Nordone; Christopher S McMahan; Michael J Yabsley
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

Review 9.  Borrelia burgdorferi Keeps Moving and Carries on: A Review of Borrelial Dissemination and Invasion.

Authors:  Jenny A Hyde
Journal:  Front Immunol       Date:  2017-02-21       Impact factor: 7.561

10.  Development and optimization of OspC chimeritope vaccinogens for Lyme disease.

Authors:  Jerilyn R Izac; Nathaniel S O'Bier; Lee D Oliver; Andrew C Camire; Christopher G Earnhart; DeLacy V LeBlanc Rhodes; Brandon F Young; Stuart R Parnham; Christopher Davies; Richard T Marconi
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.